• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经尿道膀胱肿瘤切除术后计划外再入院与哪些因素相关?一项基于大型单机构经验的分析。

What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution's experience.

作者信息

Ghali Fady, Moses Rachel A, Raffin Eric, Hyams Elias S

机构信息

a Geisel School of Medicine at Dartmouth , Hanover , NH , USA ;

b Section of Urology , Dartmouth-Hitchcock Medical Center , Lebanon , NH , USA.

出版信息

Scand J Urol. 2016 Oct;50(5):370-3. doi: 10.1080/21681805.2016.1201856. Epub 2016 Jul 20.

DOI:10.1080/21681805.2016.1201856
PMID:27438524
Abstract

OBJECTIVE

This study sought to evaluate factors associated with unplanned hospital return (UR) following transurethral resection of bladder tumor (TURBT), the largest source of readmission among ambulatory urological procedures.

MATERIALS AND METHODS

A retrospective review of TURBTs at a single academic institution between April 2011 and August 2014 was performed. Demographics, comorbidities, length of stay, tumor size and multiple other factors were recorded. UR was recorded within 30 days of surgery. Bivariate and multivariable analyses were performed to determine factors associated with UR.

RESULTS

Among 708 patients undergoing TURBT, 23.9% were female with a mean age of 70 years. The rate of UR was 10.9%. The most common cause of UR was gross hematuria, accounting for 70%. On bivariate analysis, Foley catheter placement in the operating room, non-aspirin anticoagulation and index length of stay longer than 24 h were associated with hematuria-related UR (p < 0.05). Preoperative antibiotics, female gender and aspirin therapy were associated with lower rates of hematuria-related UR (p < 0.05), while tumor size, distance of residence to the hospital, and Foley on hospital discharge (rather than from the operating room) had no association (p > 0.05). On multivariable analysis, only Foley placement in the operating room remained associated with higher rates of hematuria-related UR, while preoperative antibiotics, female gender and aspirin therapy remained associated with a lower likelihood of this event.

CONCLUSIONS

UR following TURBT is common and typically results from gross hematuria. Patients with postoperative Foley catheterization in the operating room may require additional counseling or supervision before discharge, and should be considered for discharge with a Foley rather than having a prompt voiding trial.

摘要

目的

本研究旨在评估经尿道膀胱肿瘤切除术(TURBT)后计划外再次入院(UR)的相关因素,TURBT是门诊泌尿外科手术中再入院的最大来源。

材料与方法

对2011年4月至2014年8月间在一家学术机构进行的TURBT手术进行回顾性分析。记录人口统计学、合并症、住院时间、肿瘤大小及其他多个因素。在术后30天内记录再次入院情况。进行双变量和多变量分析以确定与再次入院相关的因素。

结果

在708例行TURBT手术的患者中,23.9%为女性,平均年龄70岁。再次入院率为10.9%。再次入院最常见的原因是肉眼血尿,占70%。双变量分析显示,手术室留置Foley导管、非阿司匹林抗凝及首次住院时间超过24小时与血尿相关的再次入院有关(p<0.05)。术前使用抗生素、女性性别及阿司匹林治疗与血尿相关的再次入院率较低有关(p<0.05),而肿瘤大小、居住地与医院的距离以及出院时(而非手术室)留置Foley导管则无关联(p>0.05)。多变量分析显示,只有手术室留置Foley导管仍与血尿相关的再次入院率较高有关,而术前使用抗生素、女性性别及阿司匹林治疗仍与该事件发生的可能性较低有关。

结论

TURBT术后再次入院很常见,通常由肉眼血尿引起。在手术室术后留置Foley导管的患者在出院前可能需要额外的咨询或监督,并且应考虑出院时留置Foley导管而非立即进行排尿试验。

相似文献

1
What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution's experience.经尿道膀胱肿瘤切除术后计划外再入院与哪些因素相关?一项基于大型单机构经验的分析。
Scand J Urol. 2016 Oct;50(5):370-3. doi: 10.1080/21681805.2016.1201856. Epub 2016 Jul 20.
2
[SAFETY AND EFFICACY OF CONTINUOUS ADMINISTRATION OF ANTITHROMBOTIC DRUGS DURING TRANSURETHRAL RESECTION OF BLADDER TUMORS].[经尿道膀胱肿瘤电切术中持续应用抗血栓药物的安全性和有效性]
Nihon Hinyokika Gakkai Zasshi. 2017;108(1):17-23. doi: 10.5980/jpnjurol.108.17.
3
Short term complications from transurethral resection of bladder tumor.经尿道膀胱肿瘤切除术的短期并发症
Can J Urol. 2016 Apr;23(2):8198-203.
4
Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting.经尿道膀胱肿瘤切除术:住院医师培训环境中的术中及术后并发症
J Urol. 2005 Dec;174(6):2307-9. doi: 10.1097/01.ju.0000181797.19395.03.
5
EFFICACY OF DIFFERENT RESECTIONS ON NON-MUSCLE-INVASIVE BLADDER CANCER AND ANALYSIS OF THE OPTIMAL SURGICAL METHOD.不同切除术对非肌层浸润性膀胱癌的疗效及最佳手术方法分析
J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):465-70.
6
The risk factors of urinary tract infection after transurethral resection of bladder tumors.膀胱肿瘤经尿道电切术后尿路感染的危险因素。
World J Urol. 2019 Dec;37(12):2715-2719. doi: 10.1007/s00345-019-02737-3. Epub 2019 Mar 26.
7
Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: a population based comparison.单极与双极经尿道膀胱肿瘤切除术围手术期结果比较,包括严重膀胱损伤:基于人群的比较
J Urol. 2014 Nov;192(5):1355-9. doi: 10.1016/j.juro.2014.05.100. Epub 2014 Jun 2.
8
Transurethral Resection of Bladder Tumor Outcomes Are Predicted by a 5-Item Frailty Index.经尿道膀胱肿瘤切除术的结果可由 5 项虚弱指数预测。
Urology. 2024 Jun;188:104-110. doi: 10.1016/j.urology.2024.03.026. Epub 2024 Mar 24.
9
The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement.经尿道膀胱肿瘤切除术的围手术期发病率:对质量改进的启示
Urology. 2019 Mar;125:131-137. doi: 10.1016/j.urology.2018.10.027. Epub 2018 Oct 23.
10
Unplanned Hospital Return for Infection following Ureteroscopy-Can We Identify Modifiable Risk Factors?输尿管镜检查后感染的非计划性医院返回:我们能否确定可修改的危险因素?
J Urol. 2016 Apr;195(4 Pt 1):931-6. doi: 10.1016/j.juro.2015.09.074. Epub 2015 Sep 26.

引用本文的文献

1
Optimizing Pharmacotherapy During Implementation of Enhanced Recovery After Surgery (ERAS) in Ambulatory Urologic Oncology Surgery: Narrative Review.门诊泌尿外科肿瘤手术中实施加速康复外科(ERAS)期间的药物治疗优化:叙述性综述
Cancers (Basel). 2025 Feb 11;17(4):614. doi: 10.3390/cancers17040614.
2
[Impact of primary care nursing discharge follow-up on early hospital readmissions. Observational longitudinal study].[初级护理出院随访对早期再入院的影响。观察性纵向研究]
Aten Primaria. 2025 Feb;57(2):103083. doi: 10.1016/j.aprim.2024.103083. Epub 2024 Sep 12.
3
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.
日间 TURBT 患者的 ERAS:提高膀胱癌护理水平(EMBRACE)随机对照试验方案。
BMJ Open. 2024 Jun 10;14(6):e076763. doi: 10.1136/bmjopen-2023-076763.
4
Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection-A Prospective Study.膀胱肿瘤激光消融与经尿道切除术相比的患者报告结局——一项前瞻性研究
Cancers (Basel). 2024 Apr 24;16(9):1630. doi: 10.3390/cancers16091630.
5
A retrospective analysis of the factors associated with increased risk of readmission within 30 days after primary transurethral resection of bladder tumor.膀胱肿瘤初次经尿道切除术后30天内再入院风险增加相关因素的回顾性分析。
Curr Urol. 2023 Dec;17(4):257-261. doi: 10.1097/CU9.0000000000000160. Epub 2022 Sep 28.
6
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.采用含丝裂霉素的反向热凝胶(Optima II)UGN-102 对低级别中危非肌肉浸润性膀胱癌进行初步化学消融:一项 2b 期、开放标签、单臂试验。
J Urol. 2022 Jan;207(1):61-69. doi: 10.1097/JU.0000000000002186. Epub 2021 Aug 26.
7
Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment.阿司匹林的使用与膀胱癌的风险或预后有关吗?一项病例对照研究和荟萃分析评估。
Front Oncol. 2021 Jul 19;11:633462. doi: 10.3389/fonc.2021.633462. eCollection 2021.
8
Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours.经尿道膀胱肿瘤切除术或膀胱肿瘤内镜切除术复杂性的共识定义与预测
Cancers (Basel). 2020 Oct 20;12(10):3063. doi: 10.3390/cancers12103063.
9
Reducing readmissions and improving patient experience following urological surgery, through early telephone follow-up.通过术后早期电话随访,降低泌尿外科手术后再入院率,改善患者体验。
BMJ Open Qual. 2020 Apr;9(2). doi: 10.1136/bmjoq-2018-000533.
10
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer.血尿对阿帕齐喹酮的灭活作用:对非肌肉浸润性膀胱癌 III 期临床试验设计的影响。
Cancer Chemother Pharmacol. 2019 Jun;83(6):1183-1189. doi: 10.1007/s00280-019-03812-7. Epub 2019 Mar 13.